{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:58:37Z","timestamp":1773867517671,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.ajo.2013.10.006","type":"journal-article","created":{"date-parts":[[2013,10,18]],"date-time":"2013-10-18T21:01:42Z","timestamp":1382130102000},"page":"280-286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Long-term Follow-up of Tacrolimus Ointment for Treatment of Atopic Keratoconjunctivitis"],"prefix":"10.1016","volume":"157","author":[{"given":"Abdulrahman Mohammed","family":"Al-Amri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ajo.2013.10.006_bib1","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0161-6420(98)94017-9","article-title":"Long-term follow-up of patients with atopic keratoconjunctivitis","volume":"105","author":"Power","year":"1998","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2013.10.006_bib2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1034\/j.1600-0846.2001.70203.x","article-title":"Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin","volume":"7","author":"Kolbe","year":"2001","journal-title":"Skin Res Technol"},{"issue":"9","key":"10.1016\/j.ajo.2013.10.006_bib3","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0161-6420(98)99043-1","article-title":"A randomized, placebo-controlled trial of topical cyclosporine A in steroid-dependent atopic keratoconjunctivitis","volume":"105","author":"Hingorani","year":"1998","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2013.10.006_bib4","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ophtha.2003.05.035","article-title":"A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis","volume":"111","author":"Akpek","year":"2004","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2013.10.006_bib5","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1136\/bjo.2005.082461","article-title":"Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis","volume":"90","author":"Daniell","year":"2006","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2013.10.006_bib6","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.7164\/antibiotics.40.1249","article-title":"FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics","volume":"40","author":"Kino","year":"1987","journal-title":"J Antibiot"},{"issue":"9","key":"10.1016\/j.ajo.2013.10.006_bib7","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.7164\/antibiotics.40.1256","article-title":"FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in\u00a0vitro","volume":"40","author":"Kino","year":"1987","journal-title":"J Antibiot"},{"issue":"6","key":"10.1016\/j.ajo.2013.10.006_bib8","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.4049\/jimmunol.139.6.1797","article-title":"Novel immunosuppressive agent, FK506. In\u00a0vitro effects on the cloned T\u00a0cell activation","volume":"139","author":"Sawada","year":"1987","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.ajo.2013.10.006_bib9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0192-0561(96)84506-1","article-title":"Anti-allergic activity of cyclosporin-A metabolites and their interaction with the parent compound and FK 506","volume":"18","author":"Ezeamuzie","year":"1996","journal-title":"Int J Immunopharmacol"},{"issue":"1","key":"10.1016\/j.ajo.2013.10.006_bib10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00007890-199801150-00004","article-title":"A tacrolimus-related immunosuppressant with biochemical properties distinct from those of tacrolimus","volume":"65","author":"Peterson","year":"1998","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.ajo.2013.10.006_bib11","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/0167-5699(92)90111-J","article-title":"The mechanism of action of cyclosporin A and FK-506","volume":"13","author":"Schreiber","year":"1992","journal-title":"Immunol Today"},{"issue":"6","key":"10.1016\/j.ajo.2013.10.006_bib12","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1136\/bjo.80.6.556","article-title":"Eosinophil cationic protein in tears in allergic conjunctivitis","volume":"80","author":"Montan","year":"1996","journal-title":"Br J Ophthalmol"},{"issue":"17","key":"10.1016\/j.ajo.2013.10.006_bib13","first-page":"932","article-title":"Eosinophil cationic protein as a marker for assessing the efficacy of tacrolimus ophthalmic solution in the treatment of atopic keratoconjunctivitis","volume":"13","author":"Wakamatsu","year":"2011","journal-title":"Mol Vis"},{"issue":"5","key":"10.1016\/j.ajo.2013.10.006_bib14","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s004170050252","article-title":"Inhibitory effects of FK506 on the development of experimental allergic\/immune-mediated blepharoconjunctivitis in Lewis rats by systemic but not by topical administration","volume":"237","author":"Iwamoto","year":"1999","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2013.10.006_bib15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0002-9394(02)01982-7","article-title":"Topical tacrolimus treatment of atopic eyelid disease","volume":"135","author":"Rikkers","year":"2003","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2013.10.006_bib16","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1055\/s-2001-18665","article-title":"FK 506 ointment 0.1% - a new therapeutic option for atopic blepharitis. Clinical trial with 14 patients","volume":"218","author":"Mayer","year":"2001","journal-title":"Klin Monatsbl Augenheilkd"},{"issue":"4","key":"10.1016\/j.ajo.2013.10.006_bib17","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1468-3083.2008.02933.x","article-title":"Dramatic improvement of atopic keratoconjunctivitis after topical treatment with tacrolimus ointment restricted to the eyelids","volume":"23","author":"Zribi","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.ajo.2013.10.006_bib18","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1600-0420.2006.00699.x","article-title":"Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: a retrospective study","volume":"84","author":"Virtanen","year":"2006","journal-title":"Acta Ophthalmol Scand"},{"issue":"2","key":"10.1016\/j.ajo.2013.10.006_bib19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/ICO.0b013e318159afbb","article-title":"Tacrolimus ointment 0.03% in the eye for treatment of giant papillary conjunctivitis","volume":"27","author":"Kymionis","year":"2008","journal-title":"Cornea"},{"issue":"4","key":"10.1016\/j.ajo.2013.10.006_bib20","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/ICO.0b013e3181d83875","article-title":"Topical tacrolimus ointment for treatment of intractable atopic keratoconjunctivitis: a case report and review of the literature","volume":"30","author":"Garc\u00eda","year":"2011","journal-title":"Cornea"},{"issue":"4","key":"10.1016\/j.ajo.2013.10.006_bib21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/01.ico.0000151507.49565.6e","article-title":"Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders","volume":"24","author":"Joseph","year":"2005","journal-title":"Cornea"},{"issue":"7","key":"10.1016\/j.ajo.2013.10.006_bib22","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/02713680802149115","article-title":"Topical tacrolimus 0.03% ointment for intractable allergic conjunctivitis: an open label pilot study","volume":"33","author":"Atlas-Fox","year":"2008","journal-title":"Curr Eye Res"},{"issue":"6","key":"10.1016\/j.ajo.2013.10.006_bib23","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.ophtha.2007.07.025","article-title":"Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases","volume":"115","author":"Miyazaki","year":"2008","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2013.10.006_bib24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1089\/jop.2009.0087","article-title":"A randomized, placebo controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis","volume":"26","author":"Ohashi","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.ajo.2013.10.006_bib25","first-page":"177","article-title":"A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children","volume":"30","author":"Labcharoenwongs","year":"2012","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"7","key":"10.1016\/j.ajo.2013.10.006_bib26","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/eye.2011.75","article-title":"Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis","volume":"25","author":"Kheirkhah","year":"2011","journal-title":"Eye"},{"issue":"11","key":"10.1016\/j.ajo.2013.10.006_bib27","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1046\/j.1365-2222.2003.01698.x","article-title":"Effect of FK506 eye drops on late and delayed-type responses in ocular allergy models","volume":"33","author":"Sengoku","year":"2003","journal-title":"Clin Exp Allergy"},{"issue":"12","key":"10.1016\/j.ajo.2013.10.006_bib28","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1345\/aph.1M278","article-title":"Association between exposure to topical tacrolimus or pimecrolimus and cancers","volume":"43","author":"Rita","year":"2009","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.ajo.2013.10.006_bib29","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.0022-202X.2005.23754.x","article-title":"Pharmacokinetics of 0.1% tacrolimus ointment after first and repeated application to adults with moderate to severe atopic dermatitis","volume":"125","author":"Rubins","year":"2005","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.ajo.2013.10.006_bib30","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1365-2133.2011.10363.x","article-title":"Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors","volume":"165","author":"Tennis","year":"2011","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.ajo.2013.10.006_bib31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.ajkd.2009.02.018","article-title":"Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR","volume":"54","author":"Li","year":"2009","journal-title":"Am J Kidney Dis"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939413006879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939413006879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:10:30Z","timestamp":1757596230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939413006879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0002939413006879"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2013.10.006","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term Follow-up of Tacrolimus Ointment for Treatment of Atopic Keratoconjunctivitis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2013.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}